FDA ap­proves Tai­ho's Lon­surf with be­va­cizum­ab for metasta­t­ic col­orec­tal can­cer

The FDA on Wednes­day ap­proved Tai­ho On­col­o­gy’s Lon­surf (tri­fluri­dine and tipiracil) with be­va­cizum­ab for metasta­t­ic col­orec­tal can­cer (mCRC) in those who were pre­vi­ous­ly treat­ed with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER